Last updated: 9 May 2019 at 12:32am EST

Dr. David Poon Ph.D. Net Worth




The estimated Net Worth of David Kai Yuen Poon is at least 9.68 千$ dollars as of 6 May 2019. Dr Poon owns over 800 units of Zymeworks BC Inc stock worth over 9,680$ and over the last 6 years he sold ZYME stock worth over 0$.

Dr D ZYME stock SEC Form 4 insiders trading

Dr has made over 1 trades of the Zymeworks BC Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 800 units of ZYME stock worth 2,824$ on 6 May 2019.

The largest trade he's ever made was exercising 800 units of Zymeworks BC Inc stock on 6 May 2019 worth over 2,824$. On average, Dr trades about 400 units every 0 days since 2019. As of 6 May 2019 he still owns at least 800 units of Zymeworks BC Inc stock.

You can see the complete history of Dr Poon stock trades at the bottom of the page.





Dr. David Poon Ph.D. biography

Dr. David Poon Ph.D. is the VP of Bus. Devel. and Alliance Management at Zymeworks BC Inc.



What's Dr D's mailing address?

David's mailing address filed with the SEC is C/O ZYMEWORKS INC., 1385 WEST 8TH AVENUE, SUITE 540, VANCOUVER, A1, V6H 3V9.

Insiders trading at Zymeworks BC Inc

Over the last 6 years, insiders at Zymeworks BC Inc have traded over 15,586,802$ worth of Zymeworks BC Inc stock and bought 5,881,975 units worth 49,789,204$ . The most active insiders traders include Bros. Advisors Lp667, L.P.B...Capital, Llc Eco R1Group, Llc Green Jeremy Red.... On average, Zymeworks BC Inc executives and independent directors trade stock every 37 days with the average trade being worth of 1,629,555$. The most recent stock trade was executed by Kenneth Galbraith on 5 January 2024, trading 47,666 units of ZYME stock currently worth 576,759$.



What does Zymeworks BC Inc do?

zymeworks is a privately held biotherapeutics company that is developing best-in-class azymetric™ bi specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. the company’s novel azymetric™ and albucore™ platforms, and its proprietary zymecad™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. more information on zymeworks can be found at www.zymeworks.com.



What does Zymeworks BC Inc's logo look like?

Zymeworks BC Inc logo

Complete history of Dr Poon stock trades at Zymeworks BC Inc

日付
#
会社
インサイダー
取引
取引
株式 1株当たりの株価 合計金額 その後の株式数 ソース
6 May 2019 David Kai Yuen Poon
See Remarks
オプション行使 800 3.53$ 2,824$
6 May 2019
800


Zymeworks BC Inc executives and stock owners

Zymeworks BC Inc executives and other stock owners filed with the SEC include: